Clinicopathological Implication of Long Non-Coding RNAs SOX2 Overlapping Transcript and Its Potential Target Gene Network in Various Cancers

Abstract

Background: SOX2 overlapping transcript (SOX2-OT) produces alternatively spliced long non-coding RNAs (lncRNA). Previous studies of the prognostic role of SOX2-OT expression met with conflicting results. The aim of this study was to properly consider the prognostic role of SOX2-OT expression in several cancers. In addition, the regulative mechanism of SOX2-OT is explored. Methods: PubMed, EMBASE, and Cochrane Library and The Cancer Genome Atlas (TCGA) database were comprehensively explored to recover pertinent studies. We conducted an extensive inquiry to verify the implication of SOX2-OT expression in cancer patients by conducting a meta-analysis of 13 selected studies. Thirty-two TCGA databases were used to analyze the connection between SOX2-OT expression and both the overall survival (OS) and clinicopathological characteristics of cancer patients using R and STATA 13.0. Trial sequential analysis (TSA) was adopted in order to compute the studies' power. Results: Thirteen studies involving 1172 cancer patients and 32 TCGA cancer types involving 9676 cancer patients were eventually selected. Elevated SOX2-OT expression was significantly related to shorter OS (HR = 2.026, 95% CI: 1.691-2.428, P < 0.0001) and disease-free survival (DFS) (HR = 2.554, 95% CI: 1.261-5.174, P = 0.0092) in cancer patients. Meanwhile, TSA substantiated adequate power to demonstrate the relationship between SOX2-OT expression and OS. The cancer patients with elevated SOX2-OT expression were more likely to have advanced clinical stage (RR = 1.468, 95% CI: 1.106-1.949, P = 0.0079), earlier lymphatic metastasis (P = 0.0005), earlier distant metastasis (P < 0.0001), greater tumor size (P < 0.0001), and more extreme tumor invasion (P < 0.0001) compared to those with low SOX2-OT expression. Meta-regression and

LncRNA SOX2‐OT regulates AKT/ERK and SOX2/GLI‐1 expression, hinders therapy, and worsens clinical prognosis in malignant lung diseases

“…Similar results have reported a prognostic role for SOX2-OT in malignant diseases, with a meta-analysis which indicates that increased SOX2-OT expression is significantly associated with poor overall survival (OS), and short disease-free survival (DFS) in osteosarcoma and gastric cancer patients [32]. In the case of lung cancer, some studies have previously reported that SOX2-OT overexpression is associated with worse clinical…”

“…outcomes, suggesting a role as an independent prognostic factor, though the data remains inconclusive thus far [22,32]. The MTA3/SOX2-OT/SOX2 axis has been involved as a prognostic factor for poor clinical outcomes in esophageal squamous cell carcinoma patients [40].…”

Silenced SOX2‐OT alleviates ventricular arrhythmia associated with heart failure by inhibiting NLRP3 expression via regulating miR‐2355‐3p

“…The regulatory role played by SOX2‐OT in human diseases including bipolar disorder and schizophrenia is important 25,26 . Furthermore, SOX2‐OT can predict poor overall and disease‐free survival, and correlates with tumor development and metastasis; thus, it serves as a novel diagnostic marker and plays oncogenic roles in many cancers 27,28 . The expression of SOX2‐OT gradually increases in healthy persons, and in patients with end‐, and non‐end‐stage HF 29 .…”

Long Noncoding RNA SOX2-OT: Regulations, Functions, and Roles on Mental Illnesses, Cancers, and Diabetic Complications

“…SOX2-OT has been identified as a novel lncRNA that can serve as a prognostic biomarker for cancers. A high level of SOX2-OT correlates well with poor clinical outcomes in cancers [ 34 – 45 ]. Li et al performed a meta-analysis of 13 selected studies by a comprehensive search of PubMed, EMBASE, Cochrane Library, and TCGA and found that the elevated SOX2-OT expression is significantly related to shorter overall and disease-free survival times in cancer patients [ 45 ].…”

“…A high level of SOX2-OT correlates well with poor clinical outcomes in cancers [ 34 – 45 ]. Li et al performed a meta-analysis of 13 selected studies by a comprehensive search of PubMed, EMBASE, Cochrane Library, and TCGA and found that the elevated SOX2-OT expression is significantly related to shorter overall and disease-free survival times in cancer patients [ 45 ]. Cancer patients with high SOX2-OT expression are more likely to have an advanced clinical stage, earlier lymphatic metastasis, earlier distant metastasis, a larger tumor size, and more extreme tumor invasion than those with low SOX2-OT expression [ 45 ].…”